Correction of Severe Anemia in a Patient with End Stage Renal Disease and Myelodysplastic Syndrome

Ankita Patel, Suchita Mehta^*, Ahmad Waseef, Subodh Saggi

Department of Nephrology, SUNY Downstate Medical Center, New York, USA.

DOI: 10.4236/ojneph.2014.43018                

Abstract

Background: Anemia is a common complication of end-stage renal disease (ESRD) and is effectively managed by Erythropoietin Stimulating Agents (ESAs) and intravenous iron therapy. Management of anemia in ESRD patients with myelodysplastic syndrome (MDS) poses a unique challenge. ESAs even at extremely high doses do not result in a desired response, especially if the patients are iron-overloaded. Case: A 72-year-old man with history of ESRD and MDS on hemodialysis since September 2009 was severely anemic requiring massive doses of ESA in excess of 90,000 units/week. Iron saturation was consistently >60%; ferritin was >2500. Desferrioxamine (DFO) 125 mg IV/week was begun in November 2010. His PRBC transfusion and ESA requirements declined after the initiation of this therapy. He had 33 ER visits for PRBC transfusions (1 - 3 transfusions/visit) from September 2009 to November 2010 (average: 2.35/month), which decreased to 18 visits in 20 months (average: 0.9/month) after getting DFO. Conclusion: We report a case of MDS with ESRD on hemodialysis where anemia was managed with Desferrioxamine therapy along with ESA, after which it was noted that there was a significant reduction in the number of PRBC transfusions that the patient received along with a decrease in ESA requirements and a decrease in number of hospitalizations, which in the long term could be cost effective.

Keywords

Anemia, Desferrioxamine, ESRD

Conflicts of Interest

The authors declare no conflicts of interest.

References

[1]	El-Reshaid, K., et al. (1994) Erythropoietin Treatment in Haemodialysis Patients with Iron Overload. Acta Haematologica, 91, 130-135. http://dx.doi.org/10.1159/000204318
[2]	Malcovati, L., et al. (2005) Prognostic Factors and Life Expectancy in Myelodysplastic Syndromes Classified According to WHO Criteria: A Basis for Clinical Decision Making. Journal of Clinical Oncology, 23, 7594-7603. http://dx.doi.org/10.1200/JCO.2005.01.7038
[3]	Jabbour, E., et al. (2008) Red Blood Cell Transfusions and Iron Overload in the Treatment of Patients with Myelodysplastic Syndromes. Cancer, 112, 1089-1095. http://dx.doi.org/10.1002/cncr.23280
[4]	Alessandrino, E.P., et al. (2010) Prognostic Impact of Pre-Transplantation Transfusion History and Secondary Iron Overload in Patients with Myelodysplastic Syndrome Undergoing Allogeneic Stem Cell Transplantation: A GITMO Study. Haematologica, 95, 476-484. http://dx.doi.org/10.3324/haematol.2009.011429
[5]	Malcovati, L., et al. (2007) Time-Dependent Prognostic Scoring System for Predicting Survival and Leukemic Evolution in Myelodysplastic Syndromes. Journal of Clinical Oncology, 25, 3503-3510. http://dx.doi.org/10.1200/JCO.2006.08.5696
[6]	Badawi, M.A., et al. (2010) Red Blood Cell Transfusion Independence Following the Initiation of Iron Chelation Therapy in Myelodysplastic Syndrome. Advances in Hematology, 2010, 164045.
[7]	Jensen, P.D., Jensen, I.M. and Ellegaard, J. (1992) Desferrioxamine Treatment Reduces Blood Transfusion Requirements in Patients with Myelodysplastic Syndrome. British Journal of Haematology, 80, 121-124. http://dx.doi.org/10.1111/j.1365-2141.1992.tb06411.x
[8]	Praga, M., et al. (1987) Improvement of Anaemia with Desferrioxamine in Haemodialysis Patients. Nephrology Dialysis Transplantation, 2, 243-247.
[9]	Semenza, G.L. (1998) Hypoxia-Inducible Factor 1: Master Regulator of O2 Homeostasis. Current Opinion in Genetics & Development, 8, 588-594. http://dx.doi.org/10.1016/S0959-437X(98)80016-6
[10]	Wenger, R.H. (2000) Mammalian Oxygen Sensing, Signalling and Gene Regulation. The Journal of Experimental Biology, 203, 1253-1263.
[11]	Wang, G.L. and Semenza, G.L. (1993) Desferrioxamine Induces Erythropoietin Gene Expression and Hypoxia-Inducible Factor 1 DNA-Binding Activity: Implications for Models of Hypoxia Signal Transduction. Blood, 82, 3610-3615.
[12]	Schmid, M. (2009) Iron Chelation Therapy in MDS: What Have We Learnt Recently? Blood Reviews, 23, S21-S25. http://dx.doi.org/10.1016/S0268-960X(09)70006-2
[13]	Prus, E. and Fibach, E. (2008) Flow Cytometry Measurement of the Labile Iron Pool in Human Hematopoietic Cells. Cytometry Part A, 73, 22-27. http://dx.doi.org/10.1002/cyto.a.20491
[14]	Vreugdenhil, G., et al. (1993) Iron Chelators May Enhance Erythropoiesis by Increasing Iron Delivery to Haematopoietic Tissue and Erythropoietin Response in Iron-Loading Anaemia. Acta Haematologica, 89, 57-60. http://dx.doi.org/10.1159/000204488
[15]	Aucella, F., et al. (1999) Synergistic Effect of Desferrioxamine and Recombinant Erythropoietin on Erythroid Precursor Proliferation in Chronic Renal Failure. Nephrology Dialysis Transplantation, 14, 1171-1175. http://dx.doi.org/10.1093/ndt/14.5.1171
[16]	Ghoti, H., et al. (2010) Changes in Parameters of Oxidative Stress and Free Iron Biomarkers during Treatment with Deferasirox in Iron-Overloaded Patients with Myelodysplastic Syndromes. Haematologica, 95, 1433-1434. http://dx.doi.org/10.3324/haematol.2010.024992